Skip to content
Politically.com Search all
Menu

2025 · 3rd Quarter (July 1 - Sep 30)

PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA)

Filed by ADVANCED POLICY CONSULTING, LLC.

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-08-03 06:26:15 UTC.

Source-reported fields

Filing overview

Type
3rd Quarter - Report
Posted
Oct 8, 2025
Income
$40,000.00
Expenses
Not reported
Filing UUID
f9d2ad60-09bb-443b-b198-8415fba52cf3
Termination date
Not reported

Literal source text

Lobbying issues and bill citations

HCR · Health Issues

Monitoring healthcare legislation. Education regarding market based solutions to bring down the cost of drug prices. Education regarding the dangers of global counterfeit medications. Education regard the International Pricing Index (IPI) Model, which would import single-payer government run price controls that limit innovation and patient access to life saving therapies. Support for PBM reform. HR 2214 -- "DRUG Act" HR 1492 -- "To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program." S.832 - "EPIC Act of 2025." Education regarding the Most Favored Nation Executive Order. Reconciliation legislation -- One Big Beautiful Bill Act (H.R. 1).

Literal federal measure citations: HR 2214, HR 1492, S.832, H.R. 1

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.